![Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/sa_presentations/755/82755/slides/1.jpg?0)
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019 Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019](https://pharmashots.com/public/images/20211115230631_ogImage_33.jpg)
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
![Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire](https://mms.businesswire.com/media/20190401005264/en/396178/5/puma_logo_JPEG.jpg)